drugset / Trial / NCT03019991

Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China

NCT03019991

Phase 1 Completed 18 enrolled Ascletis Pharmaceuticals Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the Pharmacokinetics of Danoprevir in single dose (100mg QD on day 1, day 4 and day 14) and Ritonavir-boosted Danoprevir (100mg QD on day 4 and day 14) in single and multiple doses (100mg BID on day 5 -day 13) in healthy volunteers.

Timeline

Start
2015-10
Primary completion
2015-11
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject danoprevir Small molecule 100 mg Oral
Background Ritonavir Other / unclassified 100 mg Oral

Indications

No indication recorded.